Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific is asking shareholders to vote on electing 11 directors, approving an advisory say‑on‑pay resolution, and ratifying its independent auditors at the 2026 virtual annual meeting. The proxy highlights 2025 results, with revenue up 4% to $44.56 billion, GAAP diluted EPS rising 7% to $17.74, adjusted EPS of $22.87, and free cash flow of $6.34 billion. The company deployed about $16.5 billion of capital, including $13 billion for M&A such as the Filtration and Separation business from Solventum and an agreement to acquire Clario, and returned $3.6 billion via buybacks and dividends, achieving 11.3% adjusted ROIC. The Board emphasizes strong governance, active refreshment, and extensive shareholder engagement after only about 36% support on the 2025 say‑on‑pay vote, leading to 2026 compensation design changes and a long‑dated, performance‑based CEO retention grant tied to relative TSR versus the S&P 500.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a grant of 89.780 Phantom Stock Units, each convertible into one share of Common Stock. The units were credited on the director’s deferred compensation account at a price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors.
Following this grant, Sperling now holds a total of 17,591.800 stock units in this account. These units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or if there is a change of control.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 66.02 Phantom Stock Units tied to common shares. These units were credited on March 28, 2026 at a reference price of $473.36 per unit under the company’s Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock and is distributable as stock when his board service ends or upon a change of control. Following this grant, Alexandra holds a total of 1,270.44 Phantom Stock Units directly.
Lynch Karen S reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Karen S. Lynch received 66.02 Phantom Stock Units tied to common stock as deferred compensation. These units are credited under the company’s Deferred Compensation Plan for Directors at $473.36 per unit and are convertible into common stock on a 1-for-1 basis.
Following this grant, Lynch holds a total of 291.49 phantom units. The units are scheduled to be distributed in stock after her board service ends for any reason or upon a change of control, aligning compensation with long-term shareholder value.
JOHNSON JENNIFER M reported acquisition or exercise transactions in this Form 4 filing.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson received a grant of 66.0200 Phantom Stock Units on March 28, 2026. These units are convertible into Common Stock on a 1-for-1 basis and were credited at $473.36 per unit under the Deferred Compensation Plan for Directors.
Following this grant, Johnson holds a total of 661.3100 Phantom Stock Units. Directors’ retainers are deferred quarterly as Common Stock units based on the closing stock price at quarter end, with shares distributed as stock after director service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 79.2200 Phantom Stock Units on March 28, 2026, as a deferred director retainer. These units are credited under the company’s Deferred Compensation Plan for Directors at a price of $473.36 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this award, Weisler holds a total of 2,717.8900 phantom stock units, which will be distributable as company stock when his board service ends or if there is a change of control.
Thermo Fisher Scientific Inc: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A reporting that it beneficially owns 0 shares of Thermo Fisher common stock, representing 0% of the class as reported. The amendment follows an internal realignment on January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries and business divisions to report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing states the disaggregated entities pursue the same investment strategies previously pursued by The Vanguard Group, Inc.
Thermo Fisher Scientific has completed its acquisition of Clario Holdings, Inc., a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earn-out and other performance-based payments. The deal also includes a further $125 million payment due in January 2027 and up to $400 million of earn-out payments tied to Clario’s results in 2026 and 2027.
Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment, enhancing its clinical research data capabilities. Thermo Fisher expects the transaction to generate a double-digit internal rate of return, be accretive to adjusted operating margin, add $0.45 of adjusted EPS in the first year after close, and deliver about $175 million of adjusted operating income synergies by year five.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer sold 1,607 shares of common stock in an open-market transaction. The sale occurred at a price of $499.40 per share, and followed a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025.
After this transaction, Shafer directly holds 20,949.9546 Thermo Fisher Scientific shares. Because the trade was executed under a Rule 10b5-1 plan, its timing reflects a preset schedule rather than a discretionary market-timing decision.